nach oben

Erschienen in:

01.09.2008

IgA Anti-b2GPI Antibodies in Patients with Autoimmune Liver Diseases

verfasst von: Stella Gabeta, Gary L. Norman, Nikolaos Gatselis, Christos Liaskos, Panagiotis A. Papamichalis, Athanasios Garagounis, Kalliopi Zachou, Eirini I. Rigopoulou, George N. Dalekos

Erschienen in: Journal of Clinical Immunology | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Recently, we reported a high prevalence of immunoglobulin G and/or immunoglobulin M anticardiolipin antibodies (aCL) in patients with autoimmune liver diseases, namely, autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC), which were independent of the respective isotypes of antibodies against β2-glycoprotein I (anti-b2GPI). Immunoglobulin A (IgA) aCL and IgA anti-b2GPI are the least studied of the three specific isotypes either in antiphospholipid syndrome (APS) or in other conditions.

Methods

Therefore, we investigated the prevalence and clinical significance of IgA anti-b2GPI and IgA aCL by enzyme-linked immunosorbent assays in another set of Caucasian patients with autoimmune liver diseases (59 AIH, 96 PBC, and 37 PSC). The disease controls group consisted of 50 hepatitis C virus (HCV) patients, 50 hepatitis B virus (HBV), 30 alcoholic liver disease (ALD), 30 non-alcoholic steatohepatitis (NASH), and 110 healthy controls.

Results and Discussion

IgA anti-b2GPI prevalence was higher in AIH (50.8%) compared to PBC (p = 0.005), PSC (p = 0.008), NASH (p = 0.004), ALD (p = 0.01), and HCV (p = 0.002). The titers were also significantly higher in AIH compared to any other group of the study. IgA aCL prevalence was higher in AIH (33.9%) compared to PBC (p = 0.005), PSC (p = 0.014), NASH (p = 0.001), ALD (p = 0.004), and HCV (p < 0.001). IgA anti-b2GPI or IgA aCL were not associated with APS features in patients with liver autoimmunity. Of note, IgA anti-b2GPI and IgA aCL were associated with clinical and biochemical markers of disease severity in AIH and PBC. We demonstrated a high prevalence and high titers of IgA anti-b2GPI in patients with AIH compared to any other liver disease of the study.

Conclusion

IgA anti-b2GPI and IgA aCL were associated with the severity and biochemical activity of AIH and PBC, but long-term prospective studies are needed to address whether this new finding is of clinical importance in AIH and PBC patients.

Miyakis S, Locksin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295–306.PubMedCrossRef

Bas de Laat H, Derksen RH, de Groot PG. β2-Glycoprotein I, the playmaker of the antiphospholipid syndrome. Clin Immunol 2004;112:161–8.PubMedCrossRef

Atsumi T, Amengual O, Yasuda S, Matsuura E, Koike T. Research around beta2-glycoprotein I: a major target for antiphospholipid antibodies. Autoimmunity 2005;38:377–81.PubMedCrossRef

Dalekos GN, Manoussakis MN, Goussia AC, Tsianos EV, Moutsopoulos HM. Soluble interleukin-2 receptors, antineutrophil cytoplasmic antibodies, and other autoantibodies in patients with ulcerative colitis. Gut 1993;34:658–64.PubMedCrossRef

Dalekos GN, Zachou K, Liaskos C. The antiphospholipid syndrome and infection. Curr Rheumatol Rep 2001;3:277–85.PubMedCrossRef

Petrovas C, Vlachogiannopoulos PG, Kordossis T, Moutsopoulos HM. Anti-phospholipid antibodies in HIV infection and SLE with or without antiphospholipid syndrome: comparisons of phospholipids specificity, avidity and reactivity with beta2-GPI. J Autoimmun 1999;13:347–55.PubMedCrossRef

Dalekos GN, Manoussakis MN, Zervou E, Tsianos EV, Moutsopoulos HM. Immunologic and viral markers in the circulation of anti-HIV negative heroin addicts. Eur J Clin Invest 1993;23:219–25.PubMedCrossRef

Zachou K, Liaskos C, Christodoulou DK, Kardasi M, Papadamou G, Gatselis N, et al. Anti-cardiolipin antibodies in patients with chronic viral hepatitis are independent of beta2-glycoprotein I cofactor or features of antiphospholipid syndrome. Eur J Clin Invest 2003;33:161–8.PubMedCrossRef

Dalekos GN, Kistis KG, Boumba DS, Voulgari P, Zervou EK, Drosos AA, et al. Increased incidence of anti-cardiolipin antibodies in patients with hepatitis C is not associated with aetiopathogenetic link to anti-phospholipid syndrome. Eur J Gastroenterol Hepatol 2000;12:67–74.PubMedCrossRef

10.

Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, et al. Bacterial induction of autoantibodies to β2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2000;109:797–804.

11.

Liaskos C, Rigopoulou E, Zachou K, Georgiadou S, Gatselis N, Papamihali R, et al. Prevalence and clinical significance of anticardiolipin antibodies in patients with type 1 autoimmune hepatitis. J Autoimmun 2005;24:251–60.PubMedCrossRef

12.

Zachou K, Liaskos C, Rigopoulou E, Gabeta S, Papamichalis P, Gatselis N, et al. Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases. Clin Immunol 2006;119:203–12.PubMedCrossRef

13.

Vlachoyiannopoulos PG, Petrovas C, Tektonidou M, Krilis SA, Moutsopoulos HM. Antibodies to β2glycoprotein I: urea resistance, binding specificity and association with thrombosis. J Clin Immunol 1998;18:308–91.CrossRef

14.

Cucnik S, Kveder T, Krizaj I, Rozman B, Bozic B. High avidity anti-β₂-glycoprotein I antibodies in patients with antiphospholipid syndrome. Ann Rheum Dis 2004;63:1478–82.PubMedCrossRef

15.

Samarkos M, Davies KA, Gordon C, Loizou S. Clinical significance of IgA anticardiolipin and anti-beta2-GPI antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rheumatol 2006;25:199–204.PubMedCrossRef

16.

Iverson GM, von Muhlen CA, Staub HL, Lassen AJ, Binder W, Norman GL. Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autantibodies that preferentially target domain 4 of beta2-GPI. J Autoimmun 2006;27:266–71.PubMedCrossRef

17.

Lakos G, Kiss E, Regeczy N, Tarjan P, Soltesz P, Zeher M, et al. Isotype distribution and clinical relevance of anti-beta2-glycoprotein I (beta2-GPI) antibodies: importance of IgA isotype. Clin Exp Immunol 1999;117:574–9.PubMedCrossRef

18.

Cucurull E, Gharavi AE, Diri E, Mendez E, Kapoor D, Espinosa LR. IgA anticardiolipin and anti-beta2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus. Am J Med Sci 1999;318:55–60.PubMedCrossRef

19.

Pahor A, Hojs R, Holc I, Ambrozic A, Cucnik S, Kveder T, et al. Antiphospholipid antibodies as a possible risk factor for atherosclerosis in patients with rheumatoid arthritis. Immunobiology 2006;211:689–94.PubMedCrossRef

20.

Straub HL, Frank M, Ranzolin A, Norman GL, Iverson GM, vonMuhlen CA. IgA antibodies to beta2-glycoprotein I and atherosclerosis. Autoimmun Rev 2006;6:104–6.CrossRef

21.

Lee RM, Branch DW, Silver RM. Immunoglobulin A anti-beta2-glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death. Am J Obstet Gynecol 2001;185:748–53.PubMedCrossRef

22.

Carmo-Pereira S, Bertolaccini ML, Escudero-Contreras A, Khamashta MA, Hughes GR. Value of IgA anticardiolipin and anti-beta2-glycoprotein I antibody testing in patients with pregnancy morbidity. Ann Rheum Dis 2003;62:540–3.PubMedCrossRef

23.

Papamichalis PA, Zachou K, Koukoulis GK, Veloni A, Karacosta EG, Kypri L, et al. The revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders. J Autoimmune Dis 2007;4:3.PubMedCrossRef

24.

Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International autoimmune hepatitis group: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929–38.PubMedCrossRef

25.

Rigopoulou EI, Davies ET, Pares A, Zachou K, Liaskos C, Bogdanos DP, et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 2005;54:528–32.PubMedCrossRef

26.

Rigopoulou EI, Davies ET, Bogdanos DP, Liaskos C, Mytilinaiou M, Koukoulis GK, et al. Anti-mitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary bilary cirrhosis. Liver Int 2007;27:1226–31.PubMed

27.

Rigopoulou EI, Bogdanos DP, Liaskos C, Koutsoumpas A, Baum H, Vergani D, et al. Anti-mitochondrial antibody immunofluorescent titres correlate with the number and intensity of immunoblot-detected mitochondrial bands in patients with primary biliary cirrhosis. Clin Chim Acta 2007;380:118–21.PubMedCrossRef

28.

Cullen S, Chapman R. Primary sclerosing cholangitis. Autoimmun Rev 2003;2:305–12.PubMedCrossRef

29.

Kyriakou DS, Alexandrakis MG, Zachou K, Passam F, Stathakis N, Dalekos GN. Hemopoietic progenitor cells and bone marrow stromal cells in patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. J Hepatol 2003;39:679–85.PubMedCrossRef

30.

Tsikrikoni A, Kyriakou DS, Rigopoulou EI, Alexandrakis MG, Zachou K, Passam F, et al. Markers of cell activation and apoptosis in bone marrow mononuclear cells of patients with autoimmune hepatitis type 1 and primary biliary cirrhosis. J Hepatol 2005;42:393–9.PubMedCrossRef

31.

Zachou K, Rigopoulou EI, Tsikrikoni A, Alexandrakis MG, Passam F, Kyriakou DS, et al. Autoimmune hepatitis type 1 and primary biliary cirrhosis have distinct bone marrow cytokine production. J Autoimmun 2005;25:283–8.PubMedCrossRef

32.

Angulo P, Peter JB, Gershwin ME, DeSotel CK, Shoenfeld Y, Ahmed AE, et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol 2000;32:182–7.PubMedCrossRef

33.

Pierangeli SS, Harris EN. Clinical laboratory testing for the antiphospholipid syndrome. Clin Chim Acta 2005;357:17–33.PubMedCrossRef

34.

Zachou K, Rigopoulou EI, Dalekos GN. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical diagnosis and to study pathogenesis of the disease. J Autoimmune Dis 2004;1:2.PubMedCrossRef

35.

Czaja AJ. Behaviour and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 1999;30:394–401.PubMedCrossRef

36.

Oertelt S, Rieger R, Selmi C, Invernizzi P, Ansari AA, Coppel RL, et al. A sensitive bead assay for antimitochondrial antibodies: chipping away at AMA-negative primary biliary cirrhosis. Hepatology 2007;45:659–65.PubMedCrossRef

37.

Wesierska-Gadek J, Penner E, Battezzati PM, Selmi C, Zuin M, Hitchman E, et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006;43:1135–44.PubMedCrossRef

38.

Tanaka A, Nezu S, Uegaki S, Mikami M, Okuyama S, Kawamura N, et al. The clinical significance of IgA antimitochondrial antibodies in sera and saliva in primary biliary cirrhosis. Ann N Y Acad Sci 2007;1107:259–70.PubMedCrossRef

39.

Shah NM, Khamashta MA, Atsumi T, Hughes GR. Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus 1998;7:3–6.PubMedCrossRef

40.

Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. New Engl J Med 2003;349:1526–33.PubMedCrossRef

Titel: IgA Anti-b2GPI Antibodies in Patients with Autoimmune Liver Diseases
verfasst von: Stella Gabeta
Gary L. Norman
Nikolaos Gatselis
Christos Liaskos
Panagiotis A. Papamichalis
Athanasios Garagounis
Kalliopi Zachou
Eirini I. Rigopoulou
George N. Dalekos
Publikationsdatum: 01.09.2008
Verlag: Springer US
Erschienen in: Journal of Clinical Immunology / Ausgabe 5/2008
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI: https://doi.org/10.1007/s10875-008-9211-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Introduction

Methods

Results and Discussion

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2008

Use of Sirolimus in IPEX and IPEX-Like Children

IkBα Promoter Polymorphisms in Patients with Primary Sjögren’s Syndrome

IL1 Gene Cluster Polymorphisms and Its Haplotypes may Predict the Risk to Develop Invasive Pulmonary Aspergillosis and Modulate C-reactive Protein Level

Histamine Release and Inflammatory Cell Infiltration in Airway Mucosa in Methylene Diphenyl Diisocyanate (MDI)-Induced Occupational Asthma

Sodium Tanshinone IIA Sulfonate Protects Mice From ConA-Induced Hepatitis via Inhibiting NF-κB and IFN-γ/STAT1 Pathways